Stock Events

Stock Events

Odonate Therapeutics 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Profitable
2017
2018
2019
2020
2021
2022
0Revenue
43.38MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4OD.MU. It's not an investment recommendation.
Apple
4
AAPL
Microsoft
3
MSFT
Ford Motor
3
F
NIO
3
NIO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap138.61B
Pfizer is a global pharmaceutical company that develops a wide range of medications, including those for cancer treatment, directly competing with Odonate's focus on cancer therapeutics.
Novartis
NVS
Mkt Cap305.1B
Novartis is a multinational pharmaceutical company that produces drugs across a variety of therapeutic areas, including oncology, making it a competitor in the cancer treatment market.
Merck
MRK
Mkt Cap319.99B
Merck is known for its strong presence in the oncology market, developing treatments that could compete with Odonate's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb is a biopharmaceutical company with a significant focus on cancer drugs, positioning it as a competitor to Odonate Therapeutics.
Roche
RHHBY
Mkt Cap341.62B
Roche Holding AG, through its pharmaceuticals division, develops cancer treatments, making it a direct competitor in the oncology sector.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca operates in various therapeutic areas, including oncology, and its development of cancer treatments competes with Odonate's offerings.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics, including for cancer, competing with Odonate's cancer focus.
AMGEN
AMGN
Mkt Cap201.93B
Amgen focuses on human therapeutics, including oncology, which puts it in direct competition with Odonate Therapeutics in the cancer treatment market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals is engaged in the development of medicines for serious medical conditions, including cancer, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical Industries is a global company that manufactures generic and specialty medicines, including oncology products, competing in the same market as Odonate.

About

Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.
Show more...
CEO
Mr. Kevin C. Tang
Employees
137
Country
United States
ISIN
US6760791060

Listings

MU
DE
4OD.MU
OTC Link
US
ODTC
OTCM
US
ODTCD

0 Comments

Share your thoughts

FAQ

What is Odonate Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Odonate Therapeutics stocks are traded under the ticker 4OD.MU.
What is Odonate Therapeutics revenue for the last year?▼
Odonate Therapeutics revenue for the last year amounts to 0 EUR.
What is Odonate Therapeutics net income for the last year?▼
4OD.MU net income for the last year is 43.38M EUR.
How many employees does Odonate Therapeutics have?▼
As of July 10, 2026, the company has 137 employees.
In which sector is Odonate Therapeutics located?▼
Odonate Therapeutics operates in the Finance & Payments sector.
When did Odonate Therapeutics complete a stock split?▼
Odonate Therapeutics has not had any recent stock splits.
Where is Odonate Therapeutics headquartered?▼
Odonate Therapeutics is headquartered in New York, United States.